These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 6584207

  • 1. Aclarubicin-associated QTc prolongation and ventricular fibrillation.
    Iwata N, Karasawa M, Omine M, Maekawa T, Suzuki T, Kawai Y.
    Cancer Treat Rep; 1984 Mar; 68(3):527-9. PubMed ID: 6584207
    [Abstract] [Full Text] [Related]

  • 2. Phase II evaluation of aclarubicin in refractory adult acute leukemia: a Southwest Oncology Group Study.
    Dabich L, Bull FE, Beltran G, Athens JW, Coltman CA, Weick JK, Van Slyck EJ, Amare M.
    Cancer Treat Rep; 1986 Aug; 70(8):967-9. PubMed ID: 3460700
    [Abstract] [Full Text] [Related]

  • 3. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H, Shimazaki C, Nakanishi S, Hamami T, Nisio A, Isemura T, Katsume H, Nakagawa M, Ijichi H.
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [Abstract] [Full Text] [Related]

  • 4. Aclarubicin in the treatment of elderly patients with acute nonlymphocytic leukemia.
    Takahashi I, Yorimitsu S, Hara M, Inagaki T, Nakada H, Sekito N, Hayashi N, Nonaka K, Ohmoto E, Uchida K.
    Acta Med Okayama; 1986 Jun; 40(3):175-7. PubMed ID: 3461685
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of aclarubicin in acute myeloblastic leukemia.
    Case DC, Ervin TJ, Boyd MA, Bove LG, Sonneborn HL, Paul SD.
    Am J Clin Oncol; 1987 Dec; 10(6):523-6. PubMed ID: 3479891
    [Abstract] [Full Text] [Related]

  • 6. Phase I-II study of aclarubicin for treatment of acute myeloid leukemia.
    Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, de Vassal F, Tapiero H, Ribaud P, Schwarzenberg L.
    Cancer Treat Rep; 1984 Jun; 68(6):881-6. PubMed ID: 6587933
    [Abstract] [Full Text] [Related]

  • 7. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP, Arlin ZA, Kempin SJ, Young CW.
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [Abstract] [Full Text] [Related]

  • 8. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M, Bao X, Rizos D, Liu F, Ziegler MG.
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [Abstract] [Full Text] [Related]

  • 9. Prevalence of QTc prolongation in adult Nigerians with chronic heart failure.
    Kolo PM, Opadijo OG, Omotoso AB, Balogun MO, Araoye MA, Katibi IA.
    West Afr J Med; 2008 Apr; 27(2):69-73. PubMed ID: 19025017
    [Abstract] [Full Text] [Related]

  • 10. Aclarubicin in single agent and combined chemotherapy of acute myeloid leukaemias.
    Mitrou PS.
    Eur J Haematol Suppl; 1987 Apr; 47():59-66. PubMed ID: 3471526
    [No Abstract] [Full Text] [Related]

  • 11. Clinical and non-invasive assessment of anthracycline cardiotoxicity: perspectives on myocardial protection.
    Mortensen SA, Aabo K, Jonsson T, Baandrup U.
    Int J Clin Pharmacol Res; 1986 Apr; 6(2):137-50. PubMed ID: 3459718
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D, Gershenzon A, Corallo CE, Nagappan R.
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [Abstract] [Full Text] [Related]

  • 13. Phase I-II study of aclacinomycin for a treatment of acute myeloid leukemia.
    Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Misset JL, de Vassal F, Tapiero H, Dorval T, Ribaud P.
    Biomed Pharmacother; 1984 Oct; 38(7):328-31. PubMed ID: 6596962
    [Abstract] [Full Text] [Related]

  • 14. Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
    Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI.
    Cancer Treat Rep; 1984 Oct; 68(10):1233-8. PubMed ID: 6597002
    [Abstract] [Full Text] [Related]

  • 15. Phase I-II study of aclarubicin for treatment of acute myeloid leukaemia.
    Machover D, Gastiaburu J, Delgado M, Goldschmidt E, Hulhoven R, Benavides M, Lotz JP, Misset JL, de Vassal F, Tapiero H.
    Eur J Haematol Suppl; 1987 Oct; 47():33-42. PubMed ID: 3471523
    [No Abstract] [Full Text] [Related]

  • 16. Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial.
    Evensen SA, Wisløff F, Müller E, Talstad I, Waage A, Johansen L.
    Eur J Haematol Suppl; 1987 Oct; 47():43-7. PubMed ID: 3471524
    [No Abstract] [Full Text] [Related]

  • 17. Effects of sevoflurane versus propofol on QT interval.
    Paventi S, Santevecchi A, Ranieri R.
    Minerva Anestesiol; 2001 Sep; 67(9):637-40. PubMed ID: 11731753
    [Abstract] [Full Text] [Related]

  • 18. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients.
    Galetta F, Franzoni F, Cervetti G, Cecconi N, Carpi A, Petrini M, Santoro G.
    Biomed Pharmacother; 2005 Dec; 59(10):541-4. PubMed ID: 16325366
    [Abstract] [Full Text] [Related]

  • 19. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation.
    Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ.
    Pacing Clin Electrophysiol; 2004 Dec; 27(12):1659-69. PubMed ID: 15613131
    [Abstract] [Full Text] [Related]

  • 20. Distribution and prognostic significance of QT intervals in the lowest half centile in 12,012 apparently healthy persons.
    Gallagher MM, Magliano G, Yap YG, Padula M, Morgia V, Postorino C, Di Liberato F, Leo R, Borzi M, Romeo F.
    Am J Cardiol; 2006 Oct 01; 98(7):933-5. PubMed ID: 16996877
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.